Related Experiment Video

Updated: Aug 15, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K

Unmet Needs in Clinical and Basic Hepatitis B Virus Research

Tung-Hung Su1,2, Jia-Horng Kao1,2,3,4

  • 1Division of Gastroenterology and Hepatology, Department of Internal Medicine.

The Journal of Infectious Diseases
|November 21, 2017
PubMed

Insights

Chronic hepatitis B (CHB) is manageable with current therapies, but unmet needs persist. Further research is crucial for optimizing treatment, improving HCC surveillance, and achieving a functional cure for CHB.

Area of Science:

  • Hepatology and Viral Hepatitis Research
  • Clinical and Translational Medicine
  • Molecular Virology

Background:

  • Chronic hepatitis B (CHB) is a treatable condition with nucleos(t)ide analogues (NUCs) and pegylated interferon, reducing disease progression and mortality.
  • Long-term NUC therapy offers effective viral suppression with few adverse effects, but significant clinical challenges remain.

Purpose of the Study:

  • To review unmet needs in the clinical management of CHB.
  • To identify key challenges in basic research for achieving a functional or complete cure of CHB.
  • To highlight areas requiring further investigation for improved patient outcomes.

Main Methods:

  • Literature review of current CHB therapies and research.
  • Analysis of existing clinical guidelines and emerging research trends.
  • Synthesis of information on challenges in basic HBV research.

Main Results:

  • Unmet needs include optimizing HCC surveillance in NUC-treated patients and defining criteria for finite-duration or combination therapies.
  • Management strategies for specific patient groups (e.g., HBeAg-positive) and biomarker integration require further study.
  • Basic research challenges involve developing better HBV models and treatments to eradicate cccDNA and achieve immunotherapy.

Conclusions:

  • Significant advancements have been made in CHB treatment, yet critical clinical and basic research gaps need addressing.
  • Achieving a functional cure (HBsAg seroclearance) and complete cure (cccDNA eradication) requires innovative approaches in virology and immunology.
  • Future research should focus on personalized treatment strategies, novel therapeutic targets, and robust preclinical models.

Keywords:
Nucleos(t)ide analoguesbiomarkercccDNAimmunotherapypegylated interferon

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Related Concept Videos

Human Virome01:26

Human Virome

The human body harbors a vast and diverse viral community known as the human virome. The virome includes bacteriophages that infect bacteria, and eukaryotic viruses that infect human cells. Transient dietary and environmental viruses also contribute to this dynamic ecosystem. Estimates suggest the human body may contain on the order of 10¹³ viral particles, though abundance varies widely by body site and detection method.Comprehensive characterization of the virome has become possible only with...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...